The present invention provides a composition comprising a synergistic combination of thymoquinone and one or more omega-3 fatty acids, wherein the molar ratio between said thymoquinone and said one or more omega-3 fatty acids is at least 1:7. The present invention also provides a method of using said composition to treat or prevent inflammatory conditions.

The present invention provides a composition comprising a synergistic combination of thymoquinone and one or more omega-3 fatty acids, wherein the molar ratio between said thymoquinone and said one or more omega-3 fatty acids is at least 1:7. The present invention also provides a method of using said composition to treat or prevent inflammatory conditions.

The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

The present disclosure provides a method for an effective decoction preparation of unripe green Mangifera indica to treat and prevent anti-SARS-CoV-2. The disclosure extends to uses of such preparation as medicaments and to methods of treating anti-SARS-CoV-2 infections, and tolerating the vaccine side-effects. The disclosure further extends to methods for preventing anti-SARS-CoV-2 infections by coating objects and surfaces with the compositions.

The present disclosure provides a method for an effective decoction preparation of unripe green Mangifera indica to treat and prevent anti-SARS-CoV-2. The disclosure extends to uses of such preparation as medicaments and to methods of treating anti-SARS-CoV-2 infections, and tolerating the vaccine side-effects. The disclosure further extends to methods for preventing anti-SARS-CoV-2 infections by coating objects and surfaces with the compositions.

The present disclosure provides a method for an effective decoction preparation of unripe green Mangifera indica to treat and prevent anti-SARS-CoV-2. The disclosure extends to uses of such preparation as medicaments and to methods of treating anti-SARS-CoV-2 infections, and tolerating the vaccine side-effects. The disclosure further extends to methods for preventing anti-SARS-CoV-2 infections by coating objects and surfaces with the compositions.

Compositions and methods for promoting skin restoration of aging skin are provided herein. Compositions and methods described herein may result in elastin and/or collagen stimulation, extracellular matrix (ECM) recycling, anti-inflammatory effects, or combinations thereof.

Compositions and methods for promoting skin restoration of aging skin are provided herein. Compositions and methods described herein may result in elastin and/or collagen stimulation, extracellular matrix (ECM) recycling, anti-inflammatory effects, or combinations thereof.

A unit dosage of an oral composition of an extract of Withania somnifera is disclosed. The extract of Withania somnifera includes total withanolides. The total withanolides includes withanolide glycosides and withanolide aglycones. The extract of Withania somnifera includes about 32% to about 38% by weight of the withanolide glycosides. Methods of preparing the extract of Withania somnifera are disclosed. Methods of treatment by administering the extract of Withania somnifera are disclosed.